Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
暂无分享,去创建一个
P. Ponikowski | G. Filippatos | S. Anker | N. Morgenthaler | A. Wu | R. Christenson | P. Clopton | A. Maisel | C. Mueller | R. Nowak | S. Di Somma | I. Anand | W. Peacock | L. Daniels | J. McCord | M. Richards | L. Ng | M. Potocki | O. Hartmann | M. Mockel | C. Hogan | S. Neath | L. Ng | A. Wu | Leong L. Ng | W. Peacock | Lori B. Daniels
[1] Oliver Hartmann,et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. , 2010, American journal of respiratory and critical care medicine.
[2] J. Struck,et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. , 2010, Journal of the American College of Cardiology.
[3] N. Morgenthaler,et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections , 2010, Critical care.
[4] T. Mueller,et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. , 2010, Clinical biochemistry.
[5] P. Ponikowski,et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.
[6] P. Ponikowski,et al. Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.
[7] L. Tavazzi,et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.
[8] N. Morgenthaler,et al. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. , 2009, Clinical biochemistry.
[9] G. Fonarow,et al. Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.
[10] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[11] J. Struck,et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2007, Journal of the American College of Cardiology.
[12] J. Struck,et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. , 2007, Journal of cardiac failure.
[13] J. Struck,et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.
[14] J. Struck,et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients , 2004, Peptides.
[15] J. Burnett,et al. Adrenomedullin: potential in physiology and pathophysiology. , 2000, Life sciences.
[16] R. Rodeheffer,et al. Cardiac secretion of adrenomedullin in human heart failure. , 1996, The Journal of clinical investigation.
[17] T. Ishimitsu,et al. Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.
[18] J. Burnett,et al. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.